231 related articles for article (PubMed ID: 19358226)
1. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).
Poluzzi E; Raschi E; Moretti U; De Ponti F
Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):512-8. PubMed ID: 19358226
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System.
Poluzzi E; Raschi E; Motola D; Moretti U; De Ponti F
Drug Saf; 2010 Apr; 33(4):303-14. PubMed ID: 20297862
[TBL] [Abstract][Full Text] [Related]
3. The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.
Raschi E; Poluzzi E; Salvo F; Koci A; Suling M; Antoniazzi S; Perina L; Hazell L; Moretti U; Sturkenboom M; Garbe E; Pariente A; De Ponti F
Drug Saf; 2016 Jan; 39(1):59-68. PubMed ID: 26446144
[TBL] [Abstract][Full Text] [Related]
4. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
Pearson EC; Woosley RL
Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.
Poluzzi E; Raschi E; Koci A; Moretti U; Spina E; Behr ER; Sturkenboom M; De Ponti F
Drug Saf; 2013 Jun; 36(6):467-79. PubMed ID: 23553446
[TBL] [Abstract][Full Text] [Related]
6. Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Teng C; Walter EA; Gaspar DKS; Obodozie-Ofoegbu OO; Frei CR
Int J Med Sci; 2019; 16(7):1018-1022. PubMed ID: 31341415
[No Abstract] [Full Text] [Related]
7. Summary of Torsades de Pointes (TdP) Reports Associated with Intravenous Drug Formulations Containing the Preservative Chlorobutanol.
Woosley RD; Romero K; Heise CW; Gallo T; Tate J; Woosley RL
Drug Saf; 2019 Jul; 42(7):907-913. PubMed ID: 30888625
[TBL] [Abstract][Full Text] [Related]
8. Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.
Ali Z; Ismail M; Khan F; Sajid H
Expert Opin Drug Saf; 2021 Jan; 20(1):101-107. PubMed ID: 33141610
[No Abstract] [Full Text] [Related]
9. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe.
Raschi E; Poluzzi E; Godman B; Koci A; Moretti U; Kalaba M; Bennie M; Barbui C; Wettermark B; Sturkenboom M; De Ponti F
PLoS One; 2013; 8(11):e81208. PubMed ID: 24278396
[TBL] [Abstract][Full Text] [Related]
10. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system.
Wu Z; Zhou P; He N; Zhai S
Front Cardiovasc Med; 2022; 9():966331. PubMed ID: 36352852
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.
Aström-Lilja C; Odeberg JM; Ekman E; Hägg S
Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):587-92. PubMed ID: 18449951
[TBL] [Abstract][Full Text] [Related]
13. Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data.
Sessler NE; Walker E; Chickballapur H; Kacholakalayil J; Coplan PM
Postgrad Med; 2017 Jan; 129(1):62-68. PubMed ID: 27977317
[TBL] [Abstract][Full Text] [Related]
14. Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting.
Kao DP; Hiatt WR; Krantz MJ
Pharmacotherapy; 2012 Aug; 32(8):767-71. PubMed ID: 22744806
[TBL] [Abstract][Full Text] [Related]
15. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
[TBL] [Abstract][Full Text] [Related]
16. First generation antipsychotic-associated serious adverse events in women: a retrospective analysis of a pharmacovigilance database.
McCall KL; Doughty BJ; Piper BJ; Naik H; Bange S; Leppien EE
Int J Clin Pharm; 2024 Apr; 46(2):515-521. PubMed ID: 38315306
[TBL] [Abstract][Full Text] [Related]
17. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
18. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.
Grouthier V; Lebrun-Vignes B; Glazer AM; Touraine P; Funck-Brentano C; Pariente A; Courtillot C; Bachelot A; Roden DM; Moslehi JJ; Salem JE
Heart; 2018 Nov; 104(22):1859-1863. PubMed ID: 29720397
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise?
Romero J; Baldinger SH; Goodman-Meza D; Engstrom K; Valencia CR; Golive A; Medrano F; Rangasamy S; Makkiya M; Fisher JD; Gross J; Krumerman A; Kim S; Garcia MJ; Di Biase L; Ferrick KJ
J Interv Card Electrophysiol; 2016 Jan; 45(1):37-45. PubMed ID: 26589717
[TBL] [Abstract][Full Text] [Related]
20. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?
Meyer-Massetti C; Cheng CM; Sharpe BA; Meier CR; Guglielmo BJ
J Hosp Med; 2010 Apr; 5(4):E8-16. PubMed ID: 20394022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]